JP7173964B2 - 抗ｐ５３抗体 - Google Patents

抗ｐ５３抗体 Download PDF

Info

Publication number
JP7173964B2
JP7173964B2 JP2019520556A JP2019520556A JP7173964B2 JP 7173964 B2 JP7173964 B2 JP 7173964B2 JP 2019520556 A JP2019520556 A JP 2019520556A JP 2019520556 A JP2019520556 A JP 2019520556A JP 7173964 B2 JP7173964 B2 JP 7173964B2
Authority
JP
Japan
Prior art keywords
polypeptide
antibody
mutant
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535241A5 (enExample
JP2019535241A (ja
Inventor
サバパシー，トル・カナガ
レイン，デビッド・ピー
ウォン，リ－アン
コー，シン・ユ
ワ，リュー・オイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2019535241A publication Critical patent/JP2019535241A/ja
Publication of JP2019535241A5 publication Critical patent/JP2019535241A5/ja
Application granted granted Critical
Publication of JP7173964B2 publication Critical patent/JP7173964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019520556A 2016-10-17 2017-10-17 抗ｐ５３抗体 Active JP7173964B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1617564.8 2016-10-17
GBGB1617564.8A GB201617564D0 (en) 2016-10-17 2016-10-17 Anti-p53 antibodies
PCT/SG2017/050522 WO2018074978A1 (en) 2016-10-17 2017-10-17 Anti-p53 antibodies

Publications (3)

Publication Number Publication Date
JP2019535241A JP2019535241A (ja) 2019-12-12
JP2019535241A5 JP2019535241A5 (enExample) 2020-11-26
JP7173964B2 true JP7173964B2 (ja) 2022-11-16

Family

ID=57680660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520556A Active JP7173964B2 (ja) 2016-10-17 2017-10-17 抗ｐ５３抗体

Country Status (7)

Country Link
US (3) US11613568B2 (enExample)
EP (1) EP3526251A4 (enExample)
JP (1) JP7173964B2 (enExample)
CN (1) CN110770252A (enExample)
GB (1) GB201617564D0 (enExample)
SG (1) SG11201903411YA (enExample)
WO (1) WO2018074978A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121268B (zh) * 2016-12-27 2023-01-31 希尔氏宠物营养品公司 宠物食品组合物
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE
GB202008688D0 (en) 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
CN113403286B (zh) * 2021-06-24 2024-01-16 新乡学院 一种靶向性三展示噬菌体及其制备方法和应用
WO2023060115A1 (en) * 2021-10-05 2023-04-13 The Penn State Research Foundation Methods for treating cancers with mutated p53
CN116178501B (zh) * 2021-11-29 2025-08-29 深圳碳云智肽药物科技有限公司 靶向p53的多肽及其在制备用于治疗癌症的药物中的应用
EP4448583A4 (en) * 2021-12-16 2025-12-17 Univ Johns Hopkins MANABODIES AGAINST P53 TUMORANTIGENS AND METHOD FOR USE
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
CN114574524A (zh) * 2022-03-14 2022-06-03 深圳市体内生物医药科技有限公司 一种从全基因组中筛选肝癌抑癌基因的方法及其应用
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533986A (ja) 2005-03-25 2008-08-28 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083709A (en) 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
JP3179481B2 (ja) 1990-06-27 2001-06-25 プリンストン ユニバーシティ 突然変異体ｐ５３検出用プローブ
AU1370592A (en) 1991-02-01 1992-09-07 Oncogene Science, Inc. Immunoassay for detection of mutant p53 polypeptide in biological fluids
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
SG11201401043SA (en) 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533986A (ja) 2005-03-25 2008-08-28 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Elena Canali et al.，SCIENTIFIC REPORTS，2014年04月22日，4 : 4729，p. 1-11
Jonas Bethuyne et al.，Nucleic Acids Research，2014年，Vol. 42, no. 20，p. 12928-12938
Philippa J. Barrell et al.，Protein Expression and Purification，2004年，Vol. 33，p. 153-159

Also Published As

Publication number Publication date
SG11201903411YA (en) 2019-05-30
US12195526B2 (en) 2025-01-14
GB201617564D0 (en) 2016-11-30
EP3526251A4 (en) 2020-06-10
WO2018074978A1 (en) 2018-04-26
US20230257457A1 (en) 2023-08-17
JP2019535241A (ja) 2019-12-12
EP3526251A1 (en) 2019-08-21
US20190248879A1 (en) 2019-08-15
CN110770252A (zh) 2020-02-07
US11613568B2 (en) 2023-03-28
US20250263475A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
US12195526B2 (en) Anti-p53 antibodies
US11072659B2 (en) Anti-PD-1 antibodies
US11142574B2 (en) Anti-TIM-3 antibodies
JP6670935B2 (ja) 抗ｐｄ−１ナノ抗体およびその使用
JP7755635B2 (ja) 抗ｈｅｒ２抗体
US11739157B2 (en) IL2Rbeta/common gamma chain antibodies
KR20170070241A (ko) 항-tim-3 항체
WO2020094834A1 (en) Il2rbeta/common gamma chain antibodies
CN110642947B (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用
EP3778646A1 (en) T cell receptor like antibodies that bind to p53-mhc class i complex
JP2013177317A (ja) 抗ｐｄｇｆ受容体抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221104

R150 Certificate of patent or registration of utility model

Ref document number: 7173964

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250